HRA Pharma Rare Diseases backs the launch of ‘Cushing’s Hub’
HRA Pharma Rare Diseases, an affiliate of HRA Pharma, has announced that it is funding the ‘Cushing’s Hub’ through an unrestricted educational grant. The hub, developed by Springer Healthcare Education, is a unique online platform that will collate all important information on Cushing’s Syndrome in one place for any medical professional to access. The platform is the first of its kind in being an online space dedicated to the discussion of all aspects of the condition.
The collaboration with Springer reflects the long-standing commitment of HRA Pharma Rare Diseases to healthcare professionals and people living with Cushing’s syndrome. Affecting less than one in 10,000 people in the EU¹, Cushing’s Syndrome is a rare and severe condition caused by prolonged high levels of cortisol in the blood and is fatal without treatment².
Cushing’s syndrome includes a variety of aetiologies of hypercortisolism which makes it challenging to manage, requiring a high level of expertise. For this reason, the launch of Cushing’s Hub will help healthcare professionals in the endocrinology field provide optimal care for patients with Cushing’s syndrome. Physicians can register on the platform for free, and it will be internationally available. (www.cushingshub.com)
The hub is managed by an independent editorial board made up of three international Cushing’s Syndrome experts; Professor Frédéric Castinetti from France; Dr Niki Karavitaki from the UK; and Associate Professor Dr Greisa Vila from Austria. This group of physicians will be responsible for choosing the content of the hub which will be regularly updated and will include news from the literature, expert editorials, full-text articles, infographics of study highlights, and videos about recent high-impact articles, as well as clinical case studies.
Professor Frédéric Castinetti, the chairman of the editorial board, says, “Anything you need to know, any question you might have about Cushing’s syndrome… you’ll find the answer on Cushing’s hub, the missing link between you and your clinic.”
Evelina Paberžė, COO of HRA Pharma Rare Diseases, says, “Cushing’s Syndrome is a chronic condition that can be fatal if left untreated. As a company which is dedicated to improving the lives of those with rare diseases, we felt it was crucial to support the development of a platform that can help healthcare professionals in the diagnosis, management and follow up of Cushing’s Syndrome. We are confident the platform will help improve the lives of many.”
About HRA Pharma Rare Diseases:
Established in July 2019, HRA Pharma Rare Diseases was created as a result of HRA Pharma’s heritage in rare diseases and its close partnerships with the community. HRA Pharma Rare Diseases has a portfolio of medicines that address Cushing’s syndrome (CS) and Adrenal Cortical Carcinoma (ACC). Now well established in Europe, the company continues to grow, with future plans to expand its geographical reach worldwide.